Patent intelligence · US
US 10675271
Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
Patent details — US 10675271
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 9, 2020
- Expiration
- Jun 4, 2040
- Applicant
- Monopar Therapeutics Inc.
- Claims
- 12
- CPC classes
- A61K, A61K2300/00, A61K31/4168, A61K45/06
Quick answer
US 10675271 (Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy) is held by Monopar Therapeutics Inc.. Status: granted. Granted Jun 9, 2020. Expires Jun 4, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Monopar Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2300/00, A61K31/4168, A61K45/06, A61P, A61P1/08
More from Monopar Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10675271?
US 10675271 (Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy) is held by Monopar Therapeutics Inc.. Status: granted. Granted Jun 9, 2020. Expires Jun 4, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10675271?
Monopar Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 10675271 expire?
Our index shows an expiration date of Jun 4, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.